Insulin Management in NPO Patients on TPN

Initial Approach to Insulin Management

For patients on NPO status and TPN, the American Diabetes Association recommends continuing basal insulin, such as glargine, at 60-80% of the usual dose to maintain basal insulin coverage while preventing hypoglycemia 1
The American Diabetes Association suggests reducing the usual insulin glargine dose to 60-80% of the patient's normal dose to account for the NPO status 1
Monitoring blood glucose at least every 4-6 hours while the patient remains NPO is recommended to detect both hyper- and hypoglycemia 1

For patients directly transitioning from oral intake to NPO/TPN, administer 60-80% of the usual long-acting insulin analog dose, as recommended by the American Diabetes Association 1

The American Diabetes Association recommends checking blood glucose every 4-6 hours while NPO 1
Using short-acting insulin as needed for hyperglycemia correction is suggested by the American Diabetes Association 1
Target blood glucose levels between 140-180 mg/dL for most hospitalized patients, as recommended by the American Diabetes Association 1
If blood glucose falls below 100 mg/dL, decrease the glargine dose by 10-20%, according to the American Diabetes Association 3

When oral intake resumes, maintain the insulin glargine but prepare to adjust the dose, as recommended by the American Society of Anesthesiologists 4, 5
The transition from IV insulin to subcutaneous insulin should occur when blood glucose levels are stable for at least 24 hours and the patient is ready to resume oral feeding, according to the American Society of Anesthesiologists 4, 5, 6

Patients with type 1 diabetes require continuous basal insulin even when NPO to prevent diabetic ketoacidosis, as stated by the American Diabetes Association 2
For patients with significant insulin resistance, maintain higher percentages of the basal insulin dose, according to the American Society of Anesthesiologists 4, 5, 6